Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810531 | 0.86 | MAPT (0.56) | MAPTSMN1; SMN2PAX8THRBPDE7A | |
| SCHEMBL2017427 | 0.86 | PAX8 (0.52) | MAPTSMN1; SMN2PAX8THRBPDE7A | |
| SCHEMBL2960875 | 0.82 | MAPT (0.70) | MAPTSMN1; SMN2THRBPDE7AHTT | |
| SCHEMBL2954774 | 0.82 | THRB (0.71) | MAPTSMN1; SMN2PAX8THRBPDE7A | |
| SCHEMBL810343 | 0.80 | MAPT (0.50) | MAPTSMN1; SMN2PDE7AHTTALDH1A1 | |
| SCHEMBL2971539 | 0.79 | HDAC1 (0.53) | MAPTSMN1; SMN2PAX8HTTALDH1A1 | |
| SCHEMBL810256 | 0.79 | PAX8 (0.50) | MAPTSMN1; SMN2PAX8THRBPDE7A | |
| SCHEMBL1455459 | 0.78 | MAPT (0.60) | MAPTSMN1; SMN2PDE7AHTTALDH1A1 | |
| SCHEMBL2962041 | 0.78 | PDE7A (0.65) | MAPTPAX8THRBPDE7AHTT | |
| SCHEMBL1455627 | 0.77 | MAPT (0.59) | MAPTSMN1; SMN2PDE7AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAPT 1347/4885SMN1; SMN2 3135/4885PAX8 3837/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | MAPT 1347/4885SMN1; SMN2 3135/4885PAX8 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.